气喘治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类别、给药方式、通路、地区及竞争格局划分，2021-2031年）

全球气喘治疗市场预计将从 2025 年的 289.2 亿美元成长到 2031 年的 379.2 亿美元，复合年增长率达到 4.62%。

此领域涵盖多种药物治疗方法和给药系统，包括吸入性皮质类固醇、支气管扩张剂和生物製药，旨在抑制慢性发炎和缓解急性气道狭窄。主要成长驱动因素包括全球呼吸系统疾病发生率的上升，而这又受到快速都市化、空气污染加剧以及环境过敏原暴露增加的影响。日益加重的疾病负担凸显了製定有效长期照护策略的必要性，并持续推动对治疗方案的需求。根据世界气喘日的数据，到2024年，气喘将影响超过2.6亿人，导致全球约45万人死亡，凸显了普及医疗保健的迫切需求。

儘管市场呈现积极的成长趋势，但现代治疗方法的成本和可及性仍然是市场面临的重大障碍。生物製药和先进吸入器的高昂价格限制了病患的用药，尤其是在医疗资源匮乏的中低收入地区。此外，患者对处方治疗方案的依从性差也是一大障碍，这不仅降低了治疗效果，也限制了製药公司的潜在收入。这些经济和行为的挑战持续阻碍全球气喘治疗产业的更广泛发展和应用。

市场驱动因素

气喘和慢性呼吸系统疾病在全球范围内的盛行率不断上升，这主要受快速都市化和环境污染物暴露增加的影响，也是市场成长的关键驱动因素。随着医疗系统努力应对日益严重的呼吸道发炎负担，不断增长的患者群体对有效的维持治疗的需求也日益迫切。现有维持治疗药物的强劲表现反映了这一趋势的商业性意义，这些药物对于日常症状管理至关重要。例如，葛兰素史克（GSK）在2025年2月报告称，其呼吸系统维持治疗药物Trelegy在2024年的销售额增长了27%，这凸显了在全球呼吸系统健康状况日益恶化的背景下，持续的疾病管理至关重要。

同时，针对重度、难治性气喘患者特定需求的生物目标和单株抗体的涌现，正在重新定义市场价值。这些精准药物旨在抑制嗜酸性粒细胞和IgE等特定发炎通路，与标准皮质类固醇相比，它们具有更优的治疗效果，从而能够实现高价定价并显着提高收入。这些新一代药物的快速普及显而易见。 2025年2月，Astra Zeneca宣布其新型生物製药TedSpir在2024年全年销售额达12.2亿美元，标誌着精准医疗正朝着个人化方向发展。此外，该领域的规模也从其旗舰产品中可见一斑。 2025年2月，再生元公司报告称，其重磅生物製药Dupixent在2024年的全球净销售额增长了22%，达到141.5亿美元，证实了精准药物将对整个市场产生重大的经济影响。

市场挑战

先进药物治疗方法和给药机制的高成本是全球气喘治疗市场发展的一大障碍。儘管临床上对生物製药和先进吸入器的需求日益增长，但这些药物的高昂成本限制了它们的使用，尤其是在医疗报销有限的地区。面对高额的自付费用，患者更有可能漏服药物或彻底放弃治疗。这种经济阻力会降低处方笺续药率，并缩小药物研发者可触及的有效市场，从而阻碍市场成长。

这种经济压力导致气喘的高发生率与实际产生收入之间出现脱节。根据美国气喘和过敏基金会估计，到2025年，美国气喘的年度经济成本将达到约820亿美元，这将造成巨大的负担，使得持续治疗的资金筹措变得困难。因此，支付方经常实施严格的处方药限制以控製成本，进一步限制了患者获得有效治疗的机会。除非经济可近性与日益增长的疾病负担之间的差距得以弥合，否则市场将难以充分发挥其商业性潜力。

市场趋势

随着製造商调整其呼吸系统药物产品组合以满足严格的环境标准，开发环保、低全球暖化潜势 (GWP) 的吸入器正在树立新的行业标准。这一趋势包括使用 HFA-152a 等先进推进剂重新设计压力定量吸入器 (pMDI)，从而在不影响临床疗效的前提下，显着降低常规治疗相关的碳排放。绿色製造和配方改良倡议的巨额投资也印证了这一行业转型。例如，凯西製药 (Chiesi Farmaceutici) 在其 2025 年 6 月发布的《2024 年永续发展报告》中重点介绍了一项超过 3.5 亿欧元的策略性投资，用于替换现有推进剂，旨在将其产品的碳足迹减少高达 90%，同时确保长期符合监管要求。

同时，高性价比的生物相似药和复杂学名药的推出，正在改变商业格局，挑战现有生物製药在重度气喘治疗领域的市场主导地位。随着关键单株抗体的专利保护到期，可互换生物相似药的核准为支付方和医疗网络提供了成本更低的治疗选择，扩大了患者获得高品质治疗的机会，而这些治疗此前曾因预算限製而受限。这种迈向可负担精准医疗的趋势也在监理层面加速推进。 2025年3月，Celltrion公司发布新闻稿，宣布其Omalizumab单抗生物相似药获得美国FDA核准，标题为「FDA核准Omliclo为首个与Zolia可互换的生物相似药」。这项重要里程碑将为原厂药带来价格竞争，并扩大生物製剂级气喘治疗的市场。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球气喘治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（短效β2受体激动剂（SABA）、长效β2受体激动剂（LABA）、吸入性皮质类固醇（ICS）、白三烯调节剂、免疫调节剂、复方药物及其他）
  • 依给药途径（吸入器、雾化器、口服药物）
  • 通路（医院药房、零售药房、网路药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球气喘治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Asthma Treatment Market is projected to expand from USD 28.92 Billion in 2025 to USD 37.92 Billion by 2031, achieving a CAGR of 4.62%. This sector encompasses a wide array of pharmacological treatments and delivery systems, such as inhaled corticosteroids, bronchodilators, and biologic agents, all aimed at controlling chronic inflammation and relieving acute airway constriction. The main forces driving this growth include the increasing global incidence of respiratory disorders, which are fueled by rapid urbanization, worsening air pollution, and higher exposure to environmental allergens. Such a rising disease burden creates a critical need for effective long-term care strategies, sustaining the demand for therapeutic solutions. Data from the Global Initiative for Asthma indicates that in 2024, the condition impacted over 260 million people and resulted in roughly 450,000 deaths worldwide, emphasizing the urgent demand for accessible medical care.

Despite these positive growth trends, the market encounters significant obstacles related to the cost and accessibility of modern therapies. The high price points of biologic medications and advanced inhaler devices limit patient access, particularly in low-to-middle-income areas where healthcare reimbursement structures are often inadequate. Additionally, poor patient adherence to prescribed treatment plans acts as a major barrier, lowering therapeutic effectiveness and constraining potential revenue for pharmaceutical companies. These combined economic and behavioral challenges continue to hinder the broader development and reach of the global asthma treatment industry.

Market Driver

The rising global prevalence of asthma and chronic respiratory conditions serves as the primary engine for market growth, underpinned by rapid urbanization and increasing exposure to environmental pollutants. This escalation in patient numbers generates a continuous, essential demand for effective maintenance treatments as healthcare systems strive to cope with the expanding burden of airway inflammation. The commercial significance of this trend is reflected in the strong performance of established maintenance therapies, which are crucial for daily symptom control. For example, GSK reported in February 2025 that sales of its respiratory maintenance product, Trelegy, grew by 27% in 2024, highlighting the vital requirement for consistent disease management amidst deteriorating global respiratory health.

Concurrently, the uptake of targeted biologic therapies and monoclonal antibodies is redefining market value by meeting the specific needs of severe, uncontrolled asthma cases. These precision medicines, designed to block specific inflammatory pathways like those involving eosinophils or IgE, provide better outcomes than standard corticosteroids, allowing for premium pricing and significant revenue expansion. The swift adoption of these next-generation drugs is evident; AstraZeneca noted in February 2025 that full-year 2024 sales for its novel biologic, Tezspire, hit $1.22 billion, signaling a transition toward personalized treatment. Furthermore, the magnitude of this segment is illustrated by leading products; Regeneron reported in February 2025 that global net sales for the blockbuster biologic Dupixent increased by 22% to $14.15 billion in 2024, confirming the major financial impact of precision therapeutics on the total market.

Market Challenge

The elevated costs associated with advanced pharmacological treatments and delivery mechanisms pose a major hurdle to the Global Asthma Treatment Market's progression. While the clinical need for biologics and modern inhalers is increasing, the high price tags of these premium options restrict their usage, especially in areas with limited healthcare reimbursement. When patients are confronted with substantial out-of-pocket costs, they are statistically more prone to skipping doses or abandoning treatment altogether. This economic friction impedes market growth by lowering prescription refill rates and effectively narrowing the addressable market for pharmaceutical developers.

This financial pressure creates a disconnect between the high disease prevalence and actual revenue generation. According to the Asthma and Allergy Foundation of America, the estimated annual economic cost of asthma in the United States reached approximately $82 billion in 2025, representing a massive burden that makes funding consistent care difficult. As a result, payers frequently implement rigorous formulary restrictions to control costs, which further limits patient access to effective therapies. Until the gap between economic accessibility and the increasing disease burden is bridged, the market will face difficulties in achieving its full commercial capabilities.

Market Trends

The creation of eco-friendly, low-global warming potential (GWP) inhalers is setting a new industry benchmark as manufacturers adjust their respiratory portfolios to meet strict environmental standards. This trend entails redesigning pressurized metered-dose inhalers (pMDIs) to use advanced propellants such as HFA-152a, which drastically lower the carbon emissions associated with daily treatment without reducing clinical effectiveness. This industry shift is demonstrated by significant investments in green manufacturing and reformulation initiatives. For instance, in its '2024 Sustainability Report' released in June 2025, Chiesi Farmaceutici highlighted a strategic investment exceeding €350 million to replace existing propellants, aiming to cut the product's carbon footprint by up to 90% while ensuring long-term regulatory adherence.

At the same time, the introduction of cost-efficient biosimilars and complex generics is transforming the commercial environment by challenging the market dominance of established biologic therapies for severe asthma. As patent protections for major monoclonal antibodies expire, the authorization of interchangeable biosimilars offers payers and healthcare networks lower-cost options, thereby broadening patient access to premium treatments that were once limited by budgetary constraints. This movement toward affordable precision medicine is gathering regulatory speed. In March 2025, Celltrion announced in a press release titled 'FDA Approves Omlyclo as First Interchangeable Biosimilar to Xolair' that it had received U.S. clearance for its omalizumab biosimilar, a key event that brings price competition to the reference product and expands the market for biologic-quality asthma care.

Key Market Players

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

Report Scope

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Class

• Short-Acting Beta-Agonists (SABA)
• Long-Acting Beta-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Leukotriene Modifiers
• Immunomodulators
• Combination Drugs
• Others

Asthma Treatment Market, By Mode of Administration

• Inhalers
• Nebulizers
• Oral Medications

Asthma Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Asthma Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Treatment Market.

Available Customizations:

Global Asthma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others)
  • 5.2.2. By Mode of Administration (Inhalers, Nebulizers, Oral Medications)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Asthma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Mode of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Asthma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Mode of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Asthma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Mode of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Asthma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Mode of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Mode of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Asthma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Mode of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Asthma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Mode of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Asthma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Mode of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Asthma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Mode of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Asthma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Mode of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Asthma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Mode of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Asthma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Mode of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Asthma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Mode of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Asthma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Mode of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Asthma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Mode of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Asthma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Mode of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Asthma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Mode of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Asthma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Mode of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Asthma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Mode of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Asthma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Mode of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Asthma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Mode of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Asthma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Mode of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Asthma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Mode of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Asthma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Mode of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Asthma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline, Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca Plc
• 15.3. Teva Pharmaceutical Industries Ltd.
• 15.4. Boehringer Ingelheim Gmbh
• 15.5. Merck & Co. Inc.
• 15.6. Novartis AG
• 15.7. Sanofi SA
• 15.8. Roche Holding AG
• 15.9. Regeneron Pharmaceutical Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer